Walvax Biotechnology Company Limited operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Walvax Biotechnology Company Limited with three other
companies in this sector in China:
Beijing SL Pharmaceutical Co Ltd
sales of 1.16 billion Chinese Renmimbi [US$170.70 million]
of which 98%
was Pharmaceuticals Industry),
Tianjin Ringpu Bio Technology Co Ltd
(792.32 million Chinese Renmimbi [US$116.95 million]
of which 60%
was Veterinary Biological Products), and
Jinyu Bio-Technology Co Ltd
(1.25 billion Chinese Renmimbi [US$183.80 million]
of which 97%
During the year ended December of 2015, sales at
Walvax Biotechnology Company Limited were 1.01 billion Chinese Renmimbi (US$148.39 million).
increase of 40.6%
versus 2014, when the company's sales were 715.23 million Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Walvax Biotechnology Company Limited
(and since 2010, sales have increased a total of 180%).
Sales of Other saw an increase
that was more than double the company's growth rate: sales were up
461.0% in 2015, from
3.70 million Chinese Renmimbi to 20.75 million Chinese Renmimbi.
Walvax Biotechnology Company Limited also saw significant increases in sales in
Vaccine Products Subcontract (up 67.5% to 578.92 million Chinese Renmimbi)